IDENTITY
CompoundDrostanolone Enanthate
EsterEnanthate
Strength200 mg/ml
FormOil Injectable Solution
ClassAnabolic Androgenic Steroid (AAS)
PHARMACOLOGY
MechanismAndrogen receptor activation
Half-lifeApproximately 5–10 days
AdministrationIntramuscular Injection (IM)
MetabolismHepatic steroid metabolism
Activity ProfileModerate anabolic and high androgenic activity
SAFETY
HPTA SuppressionSignificant suppression possible
Liver ToxicityLow compared with oral 17-alpha alkylated steroids
AromatizationNo direct estrogen conversion
Lipid ImpactPossible cholesterol changes
MonitoringHormonal and cardiovascular markers
STORAGE & PACKAGE
BrandDragon Pharma
Package10 ml Multi-dose Vial
StorageControlled room temperature
ProtectionProtect from light and excessive heat
SterilitySterile injectable oil formulation
DOSING INFORMATION
Medical UseRequires physician supervision where approved
Educational Range200–400 mg/week commonly discussed
Injection FrequencyTypically divided 1–2 times weekly
Administration RouteDeep intramuscular injection
Duration ContextOften discussed in 8–12 week protocols
CYCLE FEATURES
Onset TimeGradual effects after several weeks
Peak ActivityUsually observed during middle phase
Body CompositionAssociated with lean appearance
Water RetentionMinimal estrogen-related retention
Release ProfileLong ester sustained release
PCT PROTOCOL
PurposeSupport recovery after hormonal suppression
TimingDepends on ester clearance and individual response
Common AgentsSERM medications under medical guidance
DurationIndividualized according to laboratory results
MonitoringHormone testing recommended
STACK COMPATIBILITY
Testosterone BaseCommonly combined in research discussions
Lean Mass ApproachOften paired with non-aromatizing compounds
Estrogen ManagementRequires hormonal monitoring
Compound TypeDHT-derived steroid profile
Combination AssessmentShould consider individual health factors
MECHANISM OF ACTION
Primary TargetAndrogen receptors
Protein SynthesisInfluences anabolic signaling pathways
Androgen ActivityStrong receptor interaction
Estrogen ConversionNo aromatase conversion
Physiological EffectModifies androgenic signaling
PHARMACOKINETICS
Release ProfileSlow enanthate ester hydrolysis
AbsorptionGradual release from injection depot
Active DurationApproximately one to two weeks
Steady StateRequires repeated administration
ClearanceHepatic metabolism and elimination
CONTRAINDICATIONS
PregnancyContraindicated
Prostate DiseaseRequires medical evaluation
Cardiovascular ConditionsRisk assessment recommended
Lipid DisordersRequires monitoring
Hormonal DisordersClinical supervision required
ESTER PROFILE
Enanthate EsterLonger release duration
Compared With PropionateSlower absorption profile
Compared With AcetateExtended activity period
Main FunctionControls pharmacokinetic release
Injection PatternReduced frequency compared with short esters
CHEMICAL PROFILE
Chemical FormulaC27H44O3
Molecular Weight416.64 g/mol
CAS Number472-61-1
Chemical ClassDHT-derived anabolic steroid
Hormonal ClassAndrogenic anabolic compound
OVERVIEW
Masteron 200 by Dragon Pharma contains Drostanolone Enanthate, an injectable DHT-derived anabolic androgenic steroid characterized by a long-acting enanthate ester. The compound interacts with androgen receptors and demonstrates anabolic and androgenic activity without direct aromatization into estrogen.
BENEFITS
- Provides androgen receptor activity
- Associated with lean tissue support
- Offers a long-acting injectable profile
- Does not convert directly into estrogen
- Provides stable release characteristics
- Useful for pharmacological research discussions
POTENTIAL SIDE EFFECTS
- Suppression of natural testosterone production
- Changes in cholesterol markers
- Androgenic effects such as acne or hair changes
- Possible cardiovascular risk factors
- Mood and hormonal fluctuations
- Injection-related reactions
CONCLUSION
Dragon Pharma Masteron 200 contains Drostanolone Enanthate, a long-acting injectable DHT-derived compound with a stable pharmacokinetic profile. The enanthate ester extends release duration and provides gradual exposure following intramuscular administration.
The compound is primarily characterized by androgen receptor activity, low estrogen conversion potential and a pharmacological profile that differs from aromatizing anabolic steroids. Individual responses depend on health status, hormone balance and monitoring practices.
Appropriate medical evaluation and laboratory monitoring are important when assessing any hormone-active compound, including evaluation of cardiovascular markers, endocrine function and overall safety parameters.
Disclaimer:
This page is for informational and educational presentation only. Any pharmaceutical or hormone-related compound should only be used under licensed medical supervision and according to applicable regulations.
REFERENCES
Drostanolone pharmacological database information: DrugBank
Regulatory pharmaceutical information: FDA
Biomedical research literature: PubMed
December 15, 2025
Ran 450mg/week as part of my prep cycle. Fantastic quality with noticeable results. Secure payment options, discreet shipping, and fair pricing make this my go-to source for Masteron.